Author, year | Country | n | Chemotherapy | Hazard ratio for survival (95% CI) |
Non-anthracycline-containing polychemotherapy | ||||
Huguier M; 1980 | France | 53 | 5-FU, VBL, CTX | No significant survival difference |
Schlag P; 1982 | Germany | 98 | 5-FU, BCNU | 0.66 (0.31-1.41) |
Douglass H; 1982 | USA | 142 | 5-FU, MeCCNU | 0.58 (0.35-0.95)* |
Ochiai T; 1983 | Japan | 59 | MMC, 5-FU, Ara-C | 1.08 (0.5-2.31) |
Higgins G; 1983 | USA | 134 | 5-FU, MeCCNU | 0.94 (0.58-1.53) |
Engstrom P; 1985 | USA | 180 | 5-FU, MeCCNU | 0.94 (0.58-1.53) |
Jakesz R; 1988 | Austria | 87 | Ara-C, MMC, 5-FU | 0.65 (0.38-1.13) |
Bonfanti G; 1988 | Italy | 144 | 5-FU, MeCCNU | 0.97 (0.61-1.55) |
Allum W; 1989 | UK | 271 | MMC, 5-FU | 0.99 (0.73-1.36) |
Allum W; 1989 | UK | 270 | CTX, 5-FU, VCR, MTX¶ then MMC, 5-FU | 1.01 (0.74-1.38) |
Nakajima T; 1999 | Japan | 573 | MMC, 5-FU, UFT | 0.74 (0.5-1.09) |
Cirera L; 1999 | Spain | 148 | MMC, Ftorafur | 0.60 (0.39-0.93)* |
Nashimoto A; 2003 | Japan | 252 | MMC, 5-FU, Ara-C | No significant survival difference |
Bang Y; 2012 | Korea | 1035 | Capecitabine, oxaliplatin | 0.72 (0.52-1.00)* |
Anthracycline-containing polychemotherapy | ||||
Coombes R; 1990 | UK | 281 | 5-FU, DOX, MMC | 0.89 (0.66-1.21) |
Krook J; 1991 | USA | 125 | 5-FU, DOX | 0.97 (0.62-1.51) |
Hallissey M; 1994 | UK | 283 | 5-FU, DOX, MMC | 0.95 (0.74-1.22) |
Macdonald J; 1995 | USA | 193 | 5-FU, DOX, MMC | 0.91 (0.65-1.28) |
Lise M; 1995 | Italy | 294 | 5-FU, DOX, MMC | 0.86 (0.64-1.14) |
Tsavaris N; 1996 | Greece | 84 | 5-FU, EPI, MMC | 0.76 (0.31-1.87) |
Neri B; 1996 | Italy | 103 | 5-FU, LV, EPI | 0.46 (0.27-0.77)* |
Di Costanzo F; 2008 | Italy | 258 | PELF | 0.91 (0.64-1.26) |
Bouche O; 2005 | France | 260 | Infusional 5-FU, CIS | 0.74 (0.54-1.02) |
Nitti D; 2006 | EORTC | 206 | 5-FU, DOX, MTX | 0.89 (0.51-1.31)Δ |
Nitti D; 2006 | ICCG | 191 | 5-FU, EPI, MTX | 1.05 (0.69-1.41)Δ |
De Vita F; 2007 | GOIM | 228 | 5-FU, LV, EPI, ETOP | 0.91 (0.69-1.21) |
Kulig J; 2010 | Poland | 309 | EAP | 0.889 (0.676-1.169) |
S-1 monotherapy | ||||
Sasako M; 2011 | Japan | 1059 | S-1 | 0.67 (0.54-0.83)* |
Do you want to add Medilib to your home screen?